BiotechTube

Secukinumab

Phase 1/2Completed
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pyoderma Gangrenosum

Conditions

Pyoderma Gangrenosum

Trial Timeline

Apr 1, 2016 → Sep 19, 2019

NCT ID
NCT02733094

About Secukinumab

Secukinumab is a phase 1/2 stage product being developed by Novartis for Pyoderma Gangrenosum. The current trial status is completed. This product is registered under clinical trial identifier NCT02733094. Target conditions include Pyoderma Gangrenosum.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (20)

NCT IDPhaseStatus
NCT05583604Pre-clinicalActive
NCT07243782Pre-clinicalRecruiting
NCT06751238Phase 1Recruiting
NCT06905288Pre-clinicalRecruiting
NCT06331312Phase 3Recruiting
NCT06130540Phase 1Completed
NCT05569174Phase 3Completed
NCT05232864Phase 3Terminated
NCT05206591Phase 3Withdrawn
NCT04894890Pre-clinicalCompleted
NCT04717466ApprovedCompleted
NCT05677542Pre-clinicalCompleted
NCT05513014Pre-clinicalCompleted
NCT05320159Pre-clinicalCompleted
NCT05650060Pre-clinicalCompleted
NCT03866317Phase 2Withdrawn
NCT03769168Phase 3Completed
NCT03791060Phase 2Terminated
NCT03440736ApprovedCompleted
NCT03307447ApprovedUNKNOWN

Competing Products

11 competing products in Pyoderma Gangrenosum

See all competitors
ProductCompanyStageHype Score
IxekizumabEli LillyPhase 2
52
adalimumabAbbViePhase 3
77
sisomicinMerckApproved
85
secukinumab 150 mg (2 injections per doseNovartisPhase 2
52
DeucravacitinibBristol Myers SquibbPhase 1
32
gevokizumabXOMAPhase 2
44
gevokizumab + Placebo + gevokizumab open-labelXOMAPhase 3
69
gevokizumabXOMAPhase 3
69
gevokizumab + Placebo + gevokizumab open-labelXOMAPhase 3
69
vilobelimab + PlaceboInflaRxPhase 3
69
vilobelimabInflaRxPhase 2
44

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85